Discovery of Potential Inhibitors of CDK1 by Integrating Pharmacophore-Based Virtual Screening, Molecular Docking,...

Area of Science:

• Biochemistry
• Pharmacology
• Medicinal Chemistry

Background:

• Cyclin-Dependent Kinase 1 (CDK1) plays a crucial role in cell cycle regulation and cancer progression.
• CDK1's ability to compensate for other CDKs presents a therapeutic challenge, with no selective FDA-approved drugs currently available.
• Targeting CDK1 is a promising strategy for developing novel anti-cancer therapies.

Purpose of the Study:

• To identify selective CDK1 inhibitors through drug repurposing and structure-based design.
• To leverage existing structural data and computational methods to screen large compound libraries.
• To discover novel compounds with potent CDK1 inhibitory activity for potential cancer treatment.

Main Methods:

• Screening of approximately 280,000 compounds using 3D QSAR pharmacophores, Lipinski, ADMET, and TOPKAT filters.
• Molecular docking of 10,310 hits against the CDK1 binding site, followed by MD simulations and MM-PBSA binding energy calculations for 12 selected hits.
• In vitro kinase inhibition assays to evaluate the CDK1 inhibitory potential of 10 final hit molecules.

Main Results:

• Three compounds demonstrated significant CDK1 inhibitory potential with IC50 values below 5 μM.
• The study successfully identified potent CDK1 inhibitors from a large-scale drug repurposing effort.
• Computational methods effectively guided the selection of promising drug candidates.

Conclusions:

• The identified compounds represent potential leads for developing subtype-selective CDK1 inhibitors.
• These inhibitors may offer improved efficacy and reduced toxicity in future cancer therapies.
• Further development of these compounds could lead to new therapeutic options for cancers overexpressing CDK1.